EUVIMEDEUVIMED entdecken
Multizentrische Studie

Growth Differentiation Factor-15 Improves Prognostic Accuracy of Risk Stratification in Pulmonary Arterial Hypertension

An-Yi Wang, Jie-Ling Ma, Yue Cui, Bao-Chen Qiu, Chao Liu, Dan Lu, Yin-Jian Yang, Yu-Ping Zhou, Ze-Jian Zhang, Xi-Qi Xu, Xin Jiang, Tian-Yu Lian und 5 weitere

CHEST · 2025

DOI: 10.1016/j.chest.2025.10.031 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift CHEST, 2025. Verfasst von An-Yi Wang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical…. Hauptthemen laut MEDLINE: Growth Differentiation Factor 15, Pulmonary Arterial Hypertension, Hypertension, Pulmonary. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The etiology of pulmonary arterial hypertension (PAH) is complex and the risk is heterogeneous. Growth differentiation factor-15 (GDF-15) has been reported to be associated with the prognosis of patients with PAH, but whether the use of GDF-15 as an additional prognostic biomarker can improve preexisting PAH risk stratification remains unclear. RESEARCH QUESTION: Can the addition of GDF-15 improve the performance of existing prediction models for PAH? STUDY DESIGN AND METHODS: We conducted a nationwide, multicenter retrospective study in which 435 patients with PAH (218 in the discovery cohort and 217 in the validation cohort) were enrolled from the National Rare Diseases Registry System of China. Serum samples were collected and serum GDF-15 levels were determined. Comprehensive PAH assessments were conducted postenrollment, including right heart catheterization, World Health Organization functional class, and other relevant clinical indicators. C-indexes were used to compare the prediction power of several existing risk models with or without GDF-15 as a predictive biomarker, especially Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). RESULTS: In the discovery cohort, elevated levels of GDF-15 were significantly associated with an increased risk of mortality, with hazard ratios of 1.658 (95% CI, 1.099-2.499; P = .016) in univariate Cox analysis and 1.678 (95% CI, 1.018-2.765; P = .042) after full adjustment. The corresponding hazard ratios in the validation cohort were 1.982 (95% CI, 1.169-3.361; P = .011) and 1.817 (95% CI, 1.035-3.190; P = .038), respectively. A novel risk model incorporating GDF-15 was developed based on COMPERA, which demonstrated improved discrimination for mortality prediction and enhanced fit, with an increase in C-index from 0.743 to 0.767 in the discovery cohort and from 0.658 to 0.687 in the validation cohort. INTERPRETATION: Our results show that GDF-15 may improve the predictive effects of existing PAH risk assessment strategies on all-cause mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Growth Differentiation Factor 15Pulmonary Arterial HypertensionHypertension, PulmonaryHumansMaleFemaleRisk AssessmentRetrospective StudiesPrognosisMiddle AgedBiomarkersChinaAdultRegistries

Stichwörter der Autor:innen

COMPERAGDF-15prognostic valuepulmonary arterial hypertension

Substanzen

Growth Differentiation Factor 15BiomarkersGDF15 protein, human

Autor:innen und Institutionen

  • Department of Cardiology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Cardiovascular Medicine, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
  • Department of Cardiology, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China.
  • Institute of Clinical Medicine, National Infrastructures for Translational Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences a…
  • Neuro Cardio Vascular Diseases Center, Xuanwu Hospital, Capital Medical University, Beijing, China.
  • Center of Basic Medical Research, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.

Förderung

  • National Natural Science Foundation of China
  • CAMS Innovation Fund for Medical Sciences
  • National Key Research and Development Program of China
  • National Science and Technology Major Project

Zitieren

APA

Wang, A. Y., Ma, J. L., Cui, Y., Qiu, B. C., Liu, C., Lu, D., Yang, Y. J., Zhou, Y. P., Zhang, Z. J., Xu, X. Q., Jiang, X., Lian, T. Y., Cheng, C. Y., Sun, K., Wang, P. W., Ma, Y. J., & Jing, Z. C. (2025). Growth Differentiation Factor-15 Improves Prognostic Accuracy of Risk Stratification in Pulmonary Arterial Hypertension. CHEST. https://doi.org/10.1016/j.chest.2025.10.031

Vancouver

Wang AY, Ma JL, Cui Y, Qiu BC, Liu C, Lu D, et al. Growth Differentiation Factor-15 Improves Prognostic Accuracy of Risk Stratification in Pulmonary Arterial Hypertension. CHEST. 2025. doi:10.1016/j.chest.2025.10.031

BibTeX
@article{Wang2025,
  author = {Wang, An-Yi and Ma, Jie-Ling and Cui, Yue and Qiu, Bao-Chen and Liu, Chao and Lu, Dan and Yang, Yin-Jian and Zhou, Yu-Ping and Zhang, Ze-Jian and Xu, Xi-Qi and Jiang, Xin and Lian, Tian-Yu and Cheng, Chun-Yan and Sun, Kai and Wang, Pei-Wen and Ma, Yue-Jiao and Jing, Zhi-Cheng},
  title = {Growth Differentiation Factor-15 Improves Prognostic Accuracy of Risk Stratification in Pulmonary Arterial Hypertension},
  journal = {CHEST},
  year = {2025},
  doi = {10.1016/j.chest.2025.10.031}
}
Kostenlos starten →